<DOC>
	<DOCNO>NCT02729896</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics , immunogenicity obinutuzumab ( G ) + atezolizumab ( Atezo ) + polatuzumab vedotin ( Pola ) participant relapse refractory FL DLBCL . The study include initial dose-escalation phase design determine recommend Phase 2 dose ( RP2D ) polatuzumab vedotin treatment combination , follow expansion phase polatuzumab vedotin give RP2D . All participant receive induction treatment G + Atezo + Pola 6 cycle . FL participant achieve complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) end induction ( EOI ) DLBCL participant achieve CR PR EOI eligible receive post-induction treatment obinutuzumab + atezolizumab .</brief_summary>
	<brief_title>A Study Obinutuzumab , Polatuzumab Vedotin , Atezolizumab Relapsed Refractory Follicular Lymphoma ( FL ) Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) A21 Status 0 , 1 , 2 For participant enrol doseescalation phase : relapsed refractory FL treatment least one prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody appropriate treatment option exists determine investigator For participant enrolled expansion phase : lymphoma classify either relapse refractory FL treatment least one prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody appropriate treatment option exists determine investigator OR classify Relapsed refractory DLBCL treatment least one prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody , patient eligible second line combination chemotherapy autologous stemcell transplantation fail second line combination chemotherapy experience disease progression follow autologous stemcell transplantation Histologically document CD20positive lymphoma fluorodeoxyglucose ( FDG ) avid lymphoma ( positron emission tomography [ PET ] positive lymphoma ) least one bidimensionally measurable lesion Availability representative tumor specimen correspond pathology report retrospective central confirmation diagnosis FL DLBCL For woman postmenopausal surgically sterile : agreement remain abstinent use contraceptive method result failure rate &lt; 1 % per year treatment period &gt; = 18 month last dose obinutuzumab For men : agreement remain abstinent use contraceptive measure result failure rate &lt; 1 % per year treatment period least 5 month last dose study drug , agreement refrain donate sperm period Grade 3b follicular lymphoma History transformation indolent disease DLBCL Known CD20negative status relapse progression ; central nervous system ( CNS ) lymphoma leptomeningeal infiltration Prior allogeneic stem cell transplantation ( SCT ) , completion autologous SCT within 100 day prior Day 1 Cycle 1 ( D1C1 ) Prior anticancer therapy include : Fludarabine alemtuzumab within 12 month prior D1C1 ; radioimmunoconjugate within 12 month prior D1C1 ; monoclonal antibody antibody drug conjugate ( ADC ) within 5 halflives 4 week prior D1C1 ; radiotherapy , chemotherapy , hormonal therapy , target smallmolecule therapy within 2 week prior D1C1 ; anti program cell death protein 1 ( anti PD1 ) , anti program deathligand 1 ( PDL1 ) , anti cytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) , anti CD137/41BB agonist , antiCD40 agonist antibody Treatment systemic immunosuppressive medication , include , limited , prednisone , azathioprine , methotrexate , thalidomide , antitumor necrosis factor agent within 2 week prior D1C1 History solid organ transplantation severe allergic anaphylactic reaction humanize , chimeric , murine monoclonal antibody Active infection ; positive hepatitis B surface agent ( HbsAg ) , total hepatitis B core antibody ( HBcAb ) , hepatitis C virus ( HCV ) antibody screen ; know history HIV positive status , progressive multifocal leukoencephalopathy ( PML ) , autoimmune disease Vaccination live virus vaccine live attenuate vaccine within 28 day prior D1C1 Preexisting Grade &gt; 1 neuropathy Major surgical procedure diagnosis within 28 day prior D1C1 Inadequate hematologic function , renal function , liver function Pregnant lactating woman Life expectancy le ( &lt; ) 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>